Generic Drugs: World Market 2014-2024
& Future Prospects for Leading Companies

ジェネリック医薬品のグローバル市場(2014-2024)

◆タイトル:Generic Drugs: World Market 2014-2024
& Future Prospects for Leading Companies
◆商品コード:Visiongain-4052624
◆調査・発行会社:visiongain
◆発行日:2014年2月
◆ページ数:238
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"ジェネリック医薬品のグローバル市場(2014-2024)"について調査・分析し、エグゼクティブサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Generic drugs – new study showing you trends, R&D progress, and predicted revenues
Where’s the generic drugs market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.
Our 238 page report provides 154 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. As pharma patents expire, much opportunity remains.
Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Professor Joshua P. Cohen, PhD, Research Assistant Professor, Tufts Center for the Study of Drug Development, Boston, Massachusetts, USA
- David Gaugh, R.Ph., Senior Vice President of Science and Regulatory Affairs, Generic Pharmaceutical Association, Washington DC, USA
- Pieter Dylst, PhD, Post-doctoral Researcher, Katholieke Universiteit Leuven
What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you will discover individual revenue forecasts for 14 leading national markets to 2024:
• US
• China
• Japan
• Germany
• India
• France
• UK
• Russia
• Italy
• Brazil
• Mexico
• South Korea
• Turkey
• Spain
• Row
There will be growth in established pharma markets and in developing countries. Our analyses show that Japan, India, Mexico and Brazil, in particular, will continue to achieve high revenue growth to 2024. Events and progress worldwide will influence the market
Leading companies and potential for market growth
Overall world revenue for generic medicines will reach $199.2bn in 2014, our report reveals We predict strong revenue growth from 2014 to 2024. Rising demand for prescription drugs, expanding healthcare coverage, payers favouring generics and changes to prescribing will increase sales to 2024.
Our work shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
• Novartis
• Teva
• Actavis
• Mylan
• Abbott
• Pfizer
• Fresenius Kabi
• Hospira
• Aspen
• Sanofi
A company profile gives you the following information:
• Revenue forecast for generic drugs from 2014 to 2024
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, inc. alliances, partnerships and joint ventures
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the generics industry?
Our new report discusses issues and events affecting the generic drugs market. You will find discussions, including qualitative analyses:
• Improving regulatory processes
• Increasing demand for generic medicines due to demographic trends
• High predicted growth in emerging markets
• Price controls by governments
• Decline in pipeline of drugs nearing patent expiry
• Consolidation among pharmacies and healthcare payers
• Increasing perception of generic drugs as unsafe and low quality
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Generic Drugs: World Market 2014-2024 & Future Prospects for Leading Companies report helps you
In summary, our 238 page report gives you the following knowledge:
• Revenues forecast to 2024 for the overall world market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2024 for the leading 14 national markets – US, China, Japan, India, Germany, France, UK, Russia, Brazil, Mexico, Italy, South Korea, Turkey, Spain and RoW
• Assessment of 10 leading companies – hear about products, results and strategies inc. revenue forecasts for generic drugs to 2024
• IP policy and other regulations – see what affects market access and entry
• Patent expiry – find prominent drug brands facing generic competition
• Trends of prescribers and healthcare payers – assess developments
• Discussion of what stimulates and restrains companies and the market
• Prospects for established companies and those seeking to enter the market
• View opinions from our survey, seeing exclusive interviews with authorities
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the generic drugs market and leading companies. You find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

【レポートの目次】

1. Executive Summary
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods
1.4 Glossary of Terms in this Report
2. Introduction to Generic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 What are Generic Drugs?
2.2.1 The Early History of Generic Drugs
2.2.2 The Hatch-Waxman Act and the Rise of Generics
2.3 Criteria for Demonstrating Bioequivalence
2.4 Authorised, Branded and Unbranded Generics
2.5 Classification of Generic Drugs Markets
2.6 Generic Substitution and the Decline of Big Pharma
2.6.1 The ‘Evergreening’ of Pharmaceuticals
2.7 Regulation of Generic Drugs
2.7.1 Regulation in the US
2.7.1.1 Obtaining FDA Approval: NDAs and ANDAs
2.7.1.2 The Hatch-Waxman Act Title I: Promotion of Generic Drugs
2.7.1.3 The Hatch-Waxman Act Title II: Incentives for the Branded Industry
2.7.1.4 The Impact of the Hatch-Waxman Act on the US Market
2.7.1.5 Me First: Timing as a Crucial Factor
2.7.2 Regulation in Europe
2.7.2.1 EU Marketing Approval Procedures
2.7.2.2 The 8+2+1 Rule: EU Data Exclusivity
2.7.2.3 Supplementary Protection Certificates
2.7.2.4 Variation Between European Countries
2.7.2.5 Towards Harmonisation of Standards
2.7.2.6 A Unitary European Patent System
2.7.3 Regulation in Japan
2.7.4 Regulation in China
2.8 Compulsory Licensing
2.9 Scope of this Report
3. Generic Drugs: World Market 2014-2024
3.1 The World Generic Drugs Market in 2012 and 2013
3.2 World Generic Drugs Market: Sales Forecast 2014-2024
3.3 Geographical Breakdown of the World Generic Drugs Market
3.4 World Generic Drugs Market: National Markets Forecast 2014-2024
3.5 World Generic Drugs Market: Regional Markets Forecast 2014-2024
3.6 How Will National Market Shares Change to 2024?
3.7 How Will Regional Market Shares Change to 2024?
3.8 World Generic Drugs Market: Drivers and Restraints 2014-2024
4. Leading Generic Drug Manufacturers 2014
4.1 World Generic Drugs Market: Top 10 Companies
4.2 Novartis
4.2.1 Novartis: Revenue Shares by Segment
4.2.2 Novartis: Generic Drugs Sales Forecast 2014-2024
4.2.3 Novartis: Recent Developments
4.2.3.1 Loss of Enoxaparin Exclusivity Hits Sandoz Profits in 2012
4.2.3.2 Emphasis on Difficult-to-Manufacture Products
4.2.3.3 FDA Quality Concerns at Sandoz Manufacturing Plants
4.2.3.4 Acquisition of Fougera Pharmaceuticals in 2012
4.2.4 Novartis: Generic Drug Market Prospects to 2024
4.3 Teva
4.3.1 Teva: Revenue Shares by Segment
4.3.2 Teva: Generic Drugs Sales Forecast 2014-2024
4.3.3 Teva: Recent Developments
4.3.3.1 Expansion Through Acquisitions
4.3.3.2 High-Value Generics to Drive Teva’s Generics Growth
4.3.3.3 Generic Viagra to Launch in 2017
4.3.3.4 Teva’s Shift Towards Innovation
4.3.3.5 Copaxone Faces Generic Competition
4.3.4 Teva: Generic Drug Market Prospects to 2024
4.4 Actavis
4.4.1 Actavis: Revenue Shares by Segment
4.4.2 Actavis: Generic Drugs Sales Forecast 2014-2024
4.4.3 Actavis: Recent Developments
4.4.3.1 Actavis Rejects Valeant and Mylan Merger Offers
4.4.3.2 Actavis Acquires Warner Chilcott
4.4.3.3 Actavis’s Biosimilar Ambitions
4.4.3.4 Exiting the Chinese Generics Market
4.4.4 Actavis: Generic Drug Market Prospects to 2024
4.5 Mylan
4.5.1 Mylan: Revenue Shares by Segment
4.5.2 Mylan: Generic Drugs Sales Forecast 2014-2024
4.5.3 Mylan: Recent Developments
4.5.3.1 Mylan to Double Manufacturing Capacity by 2016
4.5.3.2 Mylan Acquires Rights to GSK’s Advair, Diskus and Seretide
4.5.3.3 Launch of Generic Copaxone in 2014
4.5.3.4 Acquisition of Agila Expands Mylan’s Injectables Business
4.5.3.5 Mylan Working with India’s Biocon on Biosimilars
4.5.4 Mylan: Generic Drug Market Prospects to 2024
4.6 Abbott
4.6.1 Abbott: Revenue Shares by Segment
4.6.2 Abbott: Generic Drugs Sales Forecast 2014-2024
4.6.3 Abbott: Recent Developments
4.6.3.1 Abbott Retains Established Products After Spinning Off AbbVie
4.6.3.2 Acquisition of Solvay Pharmaceuticals and Piramal Healthcare Solutions
4.6.4 Abbott: Generic Drug Market Prospects to 2024
4.7 Pfizer
4.7.1 Pfizer: Revenue Shares by Segment
4.7.2 Pfizer: Generic Drugs Sales Forecast 2014-2024
4.7.3 Pfizer: Recent Developments
4.7.3.1 Pfizer Spins Off Animal Health into Zoetis
4.7.3.2 Pfizer Restructures into Three Business Units
4.7.4 Pfizer: Generic Drug Market Prospects to 2024
4.8 Fresenius Kabi
4.8.1 Fresenius Kabi: Revenue Shares by Segment
4.8.2 Fresenius Kabi: Generic Drugs Sales Forecast 2014-2024
4.8.3 Fresenius Kabi: Recent Developments
4.8.3.1 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions
4.8.3.2 FDA Manufacturing Quality Concerns at Fresenius Kabi Plants
4.8.3.3 Fresenius Kabi’s Joint Venture with PT Soho Global Health
4.8.4 Fresenius Kabi: Generic Drug Market Prospects to 2024
4.9 Hospira
4.9.1 Hospira: Revenue Shares by Segment
4.9.2 Hospira: Generic Drugs Sales Forecast 2014-2024
4.9.3 Hospira: Recent Developments
4.9.3.1 Mayne Pharma and Orchid: Expansion Through Acquisitions
4.9.3.2 Javelin Pharma’s Dyloject Fails to Deliver
4.9.3.3 Manufacturing Concerns and Remediation Efforts
4.9.4 Hospira: Generic Drug Market Prospects to 2024
4.10 Aspen
4.10.1 Aspen: Revenue Shares by Segment
4.10.2 Aspen: Generic Drugs Sales Forecast 2014-2024
4.10.3 Aspen: Recent Developments
4.10.3.1 Acquisition of GSK Anti-Thrombosis Brands
4.10.3.2 Aspen Acquires Merck MSD’s Dutch API Plant
4.10.4 Aspen: Generic Drug Market Prospects to 2024
4.11 Sanofi
4.11.1 Sanofi: Revenue Shares by Segment
4.11.2 Sanofi: Generic Drugs Sales Forecast 2014-2024
4.11.3 Sanofi: Recent Developments
4.11.3.1 Acquisitions in Emerging Markets
4.11.3.2 Sanofi’s “Brazil Generics Issue”
4.11.4 Sanofi: Generic Drug Market Prospects to 2024
5. The US Generic Drugs Market 2014-2024
5.1 US Generic Drugs Market: Overview
5.2 US Generic Drugs Market: Generic Penetration by Volume
5.3 The US Generic Drugs Market: Revenue Forecast 2014-2024
5.4 US Generic Drugs Market: Drivers and Restraints
5.5 US Generic Drugs Market: Leading Companies
5.6 US Generic Drugs Market: Trends and Developments
5.6.1 High Consumer Acceptance of Generic Medicines
5.6.2 Affordable Care Act: Expanding Medicare Coverage
5.6.3 A US Biosimilars Market?
5.6.4 The ANDA Backlog
5.6.5 Generic Drug User Fee Amendments (GDUFA) 2012
5.6.6 Falling Generic Drug Prices
5.6.7 Shortages of Generic Drugs Will Restrain the Market
5.6.8 An End to ‘Pay for Delay’?
5.7 US Generic Drugs Market: Conclusions
6. Leading European Generics Markets 2014-2024
6.1 The European Generic Drugs Market: Overview
6.1.1 Europe’s Mature and Developing Generics Markets
6.1.2 Pricing Systems and Generic Penetration
6.1.2.1 The Effects of Tendering for Generic Medicines
6.1.2.2 Lower Patient Co-payments Drive Demand for Generics
6.1.3 Will Europe Move Towards Free-Pricing Systems?
6.1.4 Challenges in the European Regulatory Environment
6.1.5 Ending Pay For Delay in Europe
6.1.6 FDA and EMA Joint Data Sharing and Inspections
6.2 EU5 Generic Drugs Market Forecast 2014-2024
6.3 German Generic Drugs Market: Overview
6.3.1 German Generic Drugs Market: Sales Forecast 2014-2024
6.3.2 German Generic Drugs Market: Generic Penetration by Volume
6.3.3 German Generic Drugs Market: Generic Penetration by Value
6.3.4 German Generic Drugs Market: Leading Companies
6.4 French Generic Drugs Market: Overview
6.4.1 French Generic Drugs Market: Sales Forecast 2014-2024
6.4.2 French Generic Drugs Market: Generic Penetration by Volume
6.4.3 French Generic Drugs Market: Generic Penetration by Value
6.5 UK Generic Drugs Market: Overview
6.5.1 UK Generic Drugs Market: Sales Forecast 2014-2024
6.5.2 UK Generic Drugs Market: Generic Penetration by Volume
6.5.3 UK Generic Drugs Market: Generic Penetration by Value
6.5.4 UK Generic Drugs Market: Trends and Developments
6.5.4.1 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
6.5.4.2 Reducing Generic Drug Prices: the Drug Tariff System
6.5.4.3 The Increasing Role of Pharmacists
6.6 Italian Generic Drugs Market: Overview
6.6.1 Italian Generic Drugs Market: Sales Forecast 2014-2024
6.6.2 Italian Generic Drugs Market: Generic Penetration by Volume
6.6.3 Italian Generic Drugs Market: Generic Penetration by Value
6.7 Spanish Generic Drugs Market: Overview
6.7.1 Spanish Generic Drugs Market: Sales Forecast 2014-2024
6.7.2 Spanish Generic Drugs Market: Generic Penetration by Volume
6.7.3 Spanish Generic Drugs Market: Generic Penetration by Value
7. Leading Asia-Pacific Generics Markets 2014-2024
7.1 Japanese Generic Drugs Market: Overview
7.1.1 Japanese Generic Drugs Market: Sales Forecast 2014-2024
7.1.2 Japanese Generic Drugs Market: Generic Penetration by Volume
7.1.3 Japanese Generic Drugs Market: Generic Penetration by Value
7.1.4 Japanese Generic Drugs Market: Leading Companies
7.1.5 Japanese Generic Drugs Market: Trends and Developments
7.1.5.1 Government Initiatives Driving Generic Penetration
7.1.5.2 Japanese Attitudes to Generic Drugs
7.1.5.3 Generic Substitution by Pharmacists
7.2 Chinese Generic Drugs Market: Overview
7.2.1 Chinese Generic Drugs Market: Sales Forecast 2014-2024
7.2.2 Chinese Generic Drugs Market: Generic Penetration by Volume
7.2.3 Chinese Generic Drugs Market: Generic Penetration by Value
7.2.4 Chinese Generic Drugs Market: Trends and Developments
7.2.4.1 Compulsory Licensing of Generic Drugs
7.2.4.2 Expansion of Healthcare Coverage and Reimbursement
7.2.4.3 Growth Opportunities in Branded Generics
7.2.4.4 Price Controls and the Anhui Model
7.3 Indian Generic Drugs Market: Overview
7.3.1 Indian Generic Drugs Market: Sales Forecast 2014-2024
7.3.2 Indian Generic Drugs Market: Leading Companies
7.3.3 Indian Generic Drugs Market: Trends and Developments
7.3.3.1 Drug Prices Control Order 2013
7.3.3.2 Expansion of Healthcare Provision
7.3.3.3 Manufacturing Quality Failures

8. Emerging Generics Markets 2014-2024
8.1 Emerging Markets: A Key Growth Opportunity
8.2 Russian Generic Drugs Market: Overview
8.2.1 Russian Generic Drugs Market: Sales Forecast 2014-2024
8.2.2 Russian Generic Drugs Market: Trends and Developments
8.2.2.1 Pharma2020, Healthcare and Industry Reform
8.2.2.2 Self-Medication and Russian Pharmacy
8.3 Brazilian Generic Drugs Market: Overview
8.3.1 Brazilian Generic Drugs Market: Sales Forecast 2014-2024
8.3.2 Brazilian Generic Drugs Market: Trends and Developments
8.3.2.1 Increasing Access to Medicines
8.3.2.2 Foreign Companies Entering the Brazilian Market
8.4 Mexican Generic Drugs Market: Overview
8.4.1 Mexican Generic Drugs Market: Sales Forecast 2014-2024
8.4.2 Mexican Generic Drugs Market: Trends and Developments
8.4.2.1 International Interest in Mexico
8.4.2.2 Government Initiatives Driving Generic Use
8.5 South Korean Generic Drugs Market: Overview
8.5.1 South Korean Generic Drugs Market: Sales Forecast 2014-2024
8.5.2 South Korean Generic Drugs Market: Trends and Developments
8.5.2.1 The Evolution of Pharmaceutical Price Controls
8.5.2.2 KORUS FTA: The South Korea – US Free Trade Agreement
8.5.2.3 EU-Korea Free Trade Agreement
8.6 Turkish Generic Drugs Market: Overview
8.6.1 Turkish Generic Drugs Market: Sales Forecast 2014-2024
8.6.2 Turkish Generic Drugs Market: Trends and Developments
8.6.2.1 Regulatory Aspects of Generics in Turkey
8.6.2.2 HTP: Transforming Turkish Healthcare Provision
8.6.2.3 Price Controls in the Turkish Pharma Market
8.6.2.4 Draft Patent Law Amendments
9. Qualitative Analysis of the Generic Drugs Market 2014-2024
9.1 SWOT Analysis of the Generic Drugs Market
9.2 Strengths
9.2.1 Strong Political Support for Domestic Generic Industries
9.2.2 Improving Regulatory Processes
9.2.3 Global Presence and Manufacturing Capacity
9.2.4 Higher Growth Rates than Innovative Pharma
9.3 Weaknesses
9.3.1 Highly Competitive Industry with Low Profit Margins
9.3.2 Patent Extension and Exclusivity Create Uncertainty in Product Launch
9.3.3 Manufacturing Safety and Quality Concerns
9.3.4 Perceptions of Generic Drugs as Unsafe or Low Quality
9.4 Opportunities
9.4.1 Patent Expiration of Innovator Drugs
9.4.2 Increasing Demand for Generics due to Demographic Trends
9.4.3 High Growth in Emerging Markets
9.4.4 Biosimilars and Complex or Branded Generics
9.5 Threats
9.5.1 Price Controls by Governments
9.5.2 Decline in Pipeline of Drugs Nearing Patent Expiry
9.5.3 Defensive Patenting Strategies
9.5.4 Consolidation Among Pharmacies and Healthcare Payers
9.6 Porter’s Five Forces Analysis of the Generic Drugs Market
9.6.1 Rivalry Among Competitors [High]
9.6.2 Threat of New Entrants [High]
9.6.3 Power of Suppliers [Low]
9.6.4 Power of Buyers [Medium]
9.6.5 Threat of Substitutes [Low]
10. Research Interviews
10.1 Interview with Professor Joshua P. Cohen, PhD, Research Assistant Professor, Tufts Center for the Study of Drug Development, Boston, Massachusetts, USA
10.1.1 The US Generic Drugs Market
10.1.2 Challenges for the Generic Drugs Industry
10.1.3 The Future of the Generic Drugs Market?
10.2 Interview with David Gaugh, R.Ph., Senior Vice President of Science and Regulatory Affairs, Generic Pharmaceutical Association, Washington DC, USA
10.2.1 The US Generic Drugs Market
10.2.2 Challenges for the Generic Drugs Industry
10.2.3 The Future of the Generic Drugs Market?
10.3 Interview with Pieter Dylst, PhD, Post-doctoral Researcher, Katholieke Universiteit Leuven, Leuven, Belgium
10.3.1 The European Generic Drugs Market
10.3.2 The Future of the Generics Industry
11. Conclusions
11.1 The World Generic Drugs Market in 2012 and 2013
11.2 World Generic Drugs Market Forecast 2014-2024
11.3 Generic Penetration by Volume in Leading National Markets
11.4 Leading National Markets
11.5 Leading Generic Drug Manufacturers
11.6 The Future of the Generic Drugs Market?



List of Tables
Table 1.1 Currency Exchange Rates, 2012-2013
Table 2.1 Types of Drug Names, 2014
Table 3.1 World Generic Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 3.2 World Generic Drugs Market Forecast: Revenues ($bn) and Market Shares (%) by National Market, 2012-2013
Table 3.3 World Generic Drugs Market Forecast: Revenues ($bn) and Market Shares (%) by Region, 2012-2013
Table 3.4 World Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by National Market, 2012-2024
Table 3.5 World Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Regional Market, 2012-2024
Table 3.6 Market Shares (%) of Leading National Generic Drugs Markets, 2012, 2018 and 2024
Table 3.7 Market Shares (%) of Leading Regional Generic Drugs Markets, 2012, 2018 and 2024
Table 4.1 Top 10 Generic Drug Manufacturers: Generic Drugs Revenue ($bn), Market Share (%), 2012-2013
Table 4.2 Top 10 Generic Drug Manufacturers: Generic Drugs Revenue ($bn), Market Share (%), 2018 and 2024
Table 4.3 Novartis: Overview, 2012-2013
Table 4.4 Novartis: Revenue ($bn), Revenue Shares (%) by Segment, 2012
Table 4.5 Novartis: Generic Drugs Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 4.6 Teva: Overview, 2012-2013
Table 4.7 Teva: Revenue ($bn), Revenue Shares (%) by Segment, 2012
Table 4.8 Teva: Generic Drugs Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 4.9 Actavis: Overview, 2012-2013
Table 4.10 Actavis: Revenue ($bn), Revenue Shares (%) by Segment, 2012
Table 4.11 Actavis: Generic Drugs Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 4.12 Mylan: Overview, 2012-2013
Table 4.13 Mylan: Revenue ($bn), Revenue Shares (%) by Segment, 2012
Table 4.14 Mylan: Generic Drugs Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 4.15 Abbott: Overview, 2012-2013
Table 4.16 Abbott: Revenue ($bn), Revenue Shares (%) by Segment, 2012
Table 4.17 Abbott: Generic Drugs Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 4.18 Pfizer: Overview, 2012-2013
Table 4.19 Pfizer: Revenue ($bn), Revenue Shares (%) by Segment, 2012
Table 4.20 Pfizer: Generic Drugs Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 4.21 Fresenius Kabi: Overview, 2012-2013
Table 4.22 Fresenius Kabi: Revenue ($bn), Revenue Shares (%) by Segment, 2012
Table 4.23 Fresenius Kabi: Generic Drugs Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 4.24 Hospira: Overview, 2012-2013
Table 4.25 Hospira: Revenue ($bn), Revenue Shares (%) by Segment, 2012
Table 4.26 Hospira: Generic Drugs Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 4.27 Aspen: Overview, 2012-2013
Table 4.28 Aspen: Revenue ($bn), Revenue Shares (%) by Segment, 2013
Table 4.29 Aspen: Generic Drugs Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 4.30 Sanofi: Overview, 2012-2013
Table 4.31 Sanofi: Revenue ($bn), Revenue Shares (%) by Segment, 2012
Table 4.32 Sanofi: Generic Drugs Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 5.1 US Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Table 5.2 US Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 6.1 EU5 Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 6.2 German Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 6.3 German Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Table 6.4 German Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Table 6.5 French Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 6.6 French Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Table 6.7 French Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Table 6.8 UK Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 6.9 UK Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Table 6.10 UK Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Table 6.11 Italian Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 6.12 Italian Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Table 6.13 Italian Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Table 6.14 Spanish Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 6.15 Spanish Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Table 6.16 Spanish Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Table 7.1 Japanese Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 7.2 Japanese Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Table 7.3 Japanese Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Table 7.4 Chinese Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 7.5 Chinese Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Table 7.6 Chinese Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Table 7.7 Indian Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 8.1 Russian Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 8.2 Brazilian Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 8.3 Mexican Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 8.4 South Korean Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 8.5 Turkish Generic Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2024
Table 9.1 SWOT Analysis of the Generic Drugs Market, 2014-2024
Table 9.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2013-2024
Table 11.1 Generic Penetration by Volume in Leading National Markets (%), 2013
Table A.1 Selected Significant Patent Expiries, 2012-2016
Table A.2 Selected Significant Patent Expiries, 2010
Table A.3 Selected Significant Patent Expiries, 2011
Table A.4 Selected Significant Patent Expiries, 2012
Table A.5 Selected Significant Patent Expiries, 2013
Table A.6 Selected Significant Patent Expiries, 2014
Table A.7 Selected Significant Patent Expiries, 2015
Table A.8 Selected Significant Patent Expiries, 2016
List of Figures
Figure 2.1 EU Data Exclusivity For Generics: Possible Scenarios, 2014
Figure 3.1 World Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2012-2024
Figure 3.2 World Generic Drugs Market: Revenues ($bn) by National Market, 2013
Figure 3.3 World Generic Drugs Market: Market Shares (%) by National Market, 2013
Figure 3.4 World Generic Drugs Market: Revenues ($bn) by Region, 2013
Figure 3.5 World Generic Drugs Market: Market Shares (%) by Region, 2013
Figure 3.6 World Generic Drugs Market: Revenues ($bn) by National Market, 2012-2024
Figure 3.7 World Generic Drugs Market: Revenues ($bn) by Regional Market, 2012-2024
Figure 3.8 World Generic Drugs Market: Market Shares (%) by National Market, 2012
Figure 3.9 World Generic Drugs Market: Market Shares (%) by National Market, 2018
Figure 3.10 World Generic Drugs Market: Market Shares (%) by National Market, 2024
Figure 3.11 World Generic Drugs Market: Market Shares (%) by Regional Market, 2012
Figure 3.12 World Generic Drugs Market: Market Shares (%) by Regional Market, 2018
Figure 3.13 World Generic Drugs Market: Market Shares (%) by Regional Market, 2024
Figure 3.14 World Generic Drugs Market: Drivers and Restraints, 2014-2024
Figure 4.1 Top 10 Generic Drug Manufacturers: Market Shares (%), 2013
Figure 4.2 Top 10 Generic Drug Manufacturers: Market Shares (%), 2018
Figure 4.3 Top 10 Generic Drug Manufacturers: Market Shares (%), 2024
Figure 4.4 Novartis: Revenue Shares (%) by Segment, 2012
Figure 4.5 Novartis: Generic Drugs Revenue ($bn), AGR (%), 2012-2024
Figure 4.6 Teva: Revenue Shares (%) by Segment, 2012
Figure 4.7 Teva: Generic Drugs Revenue ($bn), AGR (%), 2012-2024
Figure 4.8 Actavis: Revenue Shares (%) by Segment, 2012
Figure 4.9 Actavis: Generic Drugs Revenue ($bn), AGR (%), 2012-2024
Figure 4.10 Mylan: Revenue Shares (%) by Segment, 2012
Figure 4.11 Mylan: Generic Drugs Revenue ($bn), AGR (%), 2012-2024
Figure 4.12 Abbott: Revenue Shares (%) by Segment, 2012
Figure 4.13 Abbott: Generic Drugs Revenue ($bn), AGR (%), 2012-2024
Figure 4.14 Pfizer: Revenue Shares (%) by Segment, 2012
Figure 4.15 Pfizer: Generic Drugs Revenue ($bn), AGR (%), 2012-2024
Figure 4.16 Fresenius Kabi: Revenue Shares (%) by Segment, 2012
Figure 4.17 Fresenius Kabi: Generic Drugs Revenue ($bn), AGR (%), 2012-2024
Figure 4.18 Hospira: Revenue Shares (%) by Segment, 2012
Figure 4.19 Hospira: Generic Drugs Revenue ($bn), AGR (%), 2012-2024
Figure 4.20 Aspen: Revenue Shares (%) by Segment, 2013
Figure 4.21 Aspen: Generic Drugs Revenue ($bn), AGR (%), 2012-2024
Figure 4.22 Sanofi: Revenue Shares (%) by Segment, 2012
Figure 4.23 Sanofi: Generic Drugs Revenue ($bn), AGR (%), 2012-2024
Figure 5.1 US Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Figure 5.2 US Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 5.3 US Generic Drugs Market: Drivers and Restraints, 2014-2024
Figure 6.1 EU5 Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 6.2 German Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 6.3 German Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Figure 6.4 German Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Figure 6.5 French Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 6.6 French Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Figure 6.7 French Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Figure 6.8 UK Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 6.9 UK Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Figure 6.10 UK Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Figure 6.11 Italian Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 6.12 Italian Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Figure 6.13 Italian Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Figure 6.14 Spanish Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 6.15 Spanish Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Figure 6.16 Spanish Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Figure 7.1 Japanese Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 7.2 Japanese Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Figure 7.3 Japanese Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Figure 7.4 Chinese Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 7.5 Chinese Generic Drugs Market: Generic Penetration by Volume (%), 2000-2013
Figure 7.6 Chinese Generic Drugs Market: Generic Penetration by Value (%), 2000-2013
Figure 7.7 Indian Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 8.1 Russian Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 8.2 Brazilian Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 8.3 Mexican Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 8.4 South Korean Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 8.5 Turkish Generic Drugs Market Forecast: Revenues ($bn), AGR (%), 2012-2024
Figure 9.1 World 65+ Population Forecast: Size (m), 2013-2024
Figure 9.2 Porter's Five Forces Analysis of the Generic Drugs Market, 2014-2024
Figure 11.1 Generic Penetration by Volume in Leading National Markets (%), 2013


【掲載企業】

Abbott Laboratories (Abbott)
AbbVie
Aché Laboratórios Farmacêuticos S.A. (Aché)
Actavis (Foshan) Pharmaceuticals Co., Ltd (subsidiary of Actavis)
Actavis plc (Actavis)
Actelion Pharmaceuticals
Advanced Medical Optics (subsidiary of Abbott)
Agila Specialties (acquired by Mylan)
Alcon (part of Novartis)
Alembic Pharmaceuticals
Allergan
Altra Investments
Amgen
Amphastar Pharmaceuticals
APP Pharmaceuticals (acquired by Fresenis Kabi)
Arrow Group (part of Actavis)
Ascent Pharmahealth (acquired by Actavis)
Aspen Pharmacare Holdings Limited (Aspen)
Astellas Pharma
AstraZeneca
Aurobindo
Aventis (part of Sanofi)
Barr Pharmaceuticals (acquired by Teva)
Bayer AG (Bayer)
Bedford Laboratories (currently part of Boehringer Ingelheim)
Bergamo Ltda
Biocon Limited (Biocon)
Bioniche Pharma Holdings Ltd (acquired by Mylan)
BMP Sunstone (acquired by Sanofi)
Boehringer Ingelheim
Bolar Pharmaceutical (now Circa Pharmaceuticals, part of Actavis)
Cephalon (acquired by Teva)
Chattem (acquired by Sanofi)
Chiron Corporation (part of Novartis)
CIBA VISION (part of Novartis)
Cipla
Claris Lifesciences Ltd (Claris)
Compañía Internacional de Comercio, S.A.P.I. de C.V. (CISCA) (acquired by Taisho)
Corporación Infarmasa (Infarmasa) (acquired by Teva)
Cubist Pharmaceuticals
Dabur Pharma (acquired by Fresenis Kabi)
Daiichi Sankyo Brazil (subsidiary of Daiichi Sankyo)
Daiichi Sankyo Co., Ltd.
Dalim BioTech
Dey Pharma (now Mylan Specialty, subsidiary of Mylan)
Dr. Reddy's Laboratories
Ebewe Pharma (acquired by Novartis)
Eden Biopharm Group (part of Actavis)
Egis Pharmaceuticals
Eisai
Elder Pharmaceuticals
Eli Lilly and Company (Lilly)
Elyson Pharmaceutical
EMS Sigma Pharma
Endo Pharmaceuticals
Eon Labs (acquired by Novartis)
Eurofarma Laboratories
F. Hoffmann-La Roche Ltd. (Roche)
Facet Biotech (acquired by Abbott)
Farmacias Similares
Fenwal (acquired by Fresenis Kabi)
Filaxis (acquired by Fresenis Kabi)
Forest Laboratories
Foshan Chanbende Development
Fougera Pharmaceuticals (acquired by Novartis)
Fresenius Kabi (division of Fresenius SE & Co. KGaA)
Fresenius SE & Co. KGaA
Fuji Pharma Co., Ltd.
Gedeon Richter
Genzyme (acquired by Sanofi)
Gilead Sciences
GlaxoSmithKline (GSK)
Greenstone (subsidiary of Pfizer)
Grupo Imperial (acquired by Taisho)
Grupo Sanborns
Grupo Uriach
H. Lundbeck A/S (Lundbeck)
Handok Pharmaceutical (acquired by Teva)
Harris Interactive Inc.
Helvepharm (part of Sanofi)
Hexal (acquired by Novartis)
Hisun-Pfizer Pharmaceuticals (Pfizer / Zhejiang Hisun joint venture)
Hospira, Inc. (Hospira)
Ilsung Pharmaceuticals
IMS Health
InnoPharma Inc.
Itero Biopharmaceuticals
Janssen Pharmaceutica (part of Johnson & Johnson)
Javelin Pharmaceuticals (acquired by Hospira)
Johnson & Johnson (J&J)
Kmart
KMS Pharmaceutical
Kos Pharmaceuticals (acquired by Abbott)
Kosei (acquired by Taisho)
Kowa Company
Krka Pharmaceuticals
Labesfal (acquired by Fresenis Kabi)
Laboratoires Servier (Servier)
Laboratorio Sanderson (acquired by Fresenis Kabi)
Laboratório Teuto Brasileiro (Teuto) (part-owned by Pfizer)
Laboratorios Best
Laboratorios Kendrick (acquired by Sanofi)
Lek (acquired by Novartis)
Lupin Pharmaceutical
Matrix Laboratories (part of Mylan)
Mayne Pharma (acquired by Hospira)
Medis (part of Actavis)
Medley (acquired by Sanofi)
Merck & Co. (Merck)
Merck KGaA
Microdose (acquired by Teva)
Momenta Pharmaceuticals
MSD (subsidiary of Merck)
Mustafa Nevzat Pharmaceuticals (MN Pharma)
Mylan Inc. (Mylan)
Mylan Laboratories Limited (subsidiary of Mylan)
Mylan Seiyaku (subsidiary of Mylan)
Mylan Technologies Inc. (subsidiary of Mylan)
Natco Pharma
Nestlé
Neurosearch A/S
Nexus Pharmaceuticals
Nichi-Iko (acquired by Sanofi)
Nippon Chemiphar Co. Ltd.
Novartis International AG (Novartis)
Novast Laboratories
Novo Nordisk
Orchid Chemicals & Pharmaceuticals (now Hospira Healthcare India, part of Hospira)
Oriel Therapeutics (acquired by Novartis)
Otsuka Pharmaceutical
Parenteral Drugs India Ltd
Patriot Pharma (part of Johnson & Johnson)
Pfizer, Inc. (Pfizer)
PGT Healthcare (Procter & Gamble / Teva joint venture)
Pharmacia & Upjohn
PharmaDerm (now part of Novartis)
Pharmagenus (division of Grupo Uriach)
Piramal Healthcare Solutions (acquired by Abbott)
PT Ethica Industry Farmasi (subsidiary of Fresenius Kabi / PT Soho Global Health
PT Soho Global Health
Purdue Pharma
Ranbaxy Farmaceutica (subsidiary of Daiichi Sankyo)
Ranbaxy Laboratories Limited (Ranbaxy) (acquired by Daiichi Sankyo)
Ratiopharm (acquired by Teva)
Ribbon (acquired by Fresenis Kabi)
S.E. Massengill Co. (now part of Prestige Brands)
Sabex Holdings (acquired by Novartis)
Salomon, Levin and Elstein (subsidiary of Teva)
Sandoz (part of Novartis)
Sanofi Mexico (subsidiary of Sanofi)
Sanofi Pasteur (acquired by Sanofi)
Sanofi S.A. (Sanofi)
Sawai Pharmaceutical Co., Ltd. (Sawai)
Schein Pharmaceutical (part of Actavis)
Shelys (part of Aspen)
Shire
Sicor (acquired by Teva)
Sigma Pharmaceuticals (acquired by Aspen)
Solvay Pharmaceuticals (acquired by Abbott)
South African Druggists (SA Druggists, part of Aspen)
Specifar Pharmaceuticals S.A. (acquired by Actavis)
STADA Arzneimittel
STARLIMS (acquired by Abbott)
Strides Arcolab
Sun Pharmaceutical Industries (Sun Pharma)
Sunovion Pharmaceuticals, Inc. (subsidiary of Dainippon Sumitomo Pharma)
Swisse Wellness ( (acquired by Teva)
Synthélabo (part of Sanofi)
Synthon
Taisho Pharmaceutical Co., Ltd. (majority owned by Teva/Kowa joint venture)
Taiyo (acquired by Teva)
Takeda Pharmaceutical
Target Corporation (Target)
Tecnofarma (acquired by Valeant)
Teva Pharmaceutical Industries (Teva)
Teva Seiyaku (subsidiary of Teva)
The Rohatyn Group
TheraDoc (part of Hospira)
Theramex (acquired by Teva)
Torrent Pharmaceuticals
Towa Pharmaceutical Co. Ltd. (Towa)
UDL Laboratories (part of Mylan)
Uteron Pharma S.A. (acquired by Actavis)
Valeant Pharmaceuticals
Veropharm
Vitacilina Corporation of America (VitaCorp) (acquired by Taisho)
Wal-Mart Stores, Inc. (Walmart)
Warner Chilcott (acquired by Actavis)
Watson Pharmaceuticals (part of Actavis)
Winthrop Pharmaceuticals (part of Sanofi)
Wockhardt
Wyeth Pharmaceuticals (part of Pfizer)
Xenon Pharmaceuticals
Zentiva (acquired by Sanofi)
Zhejiang Chiral Medicine Chemicals Co., Ltd
Zhejiang Hisum Pharmaceutical
Zoetis
Zydus Cadila
Other Organisations Mentioned in this Report
American Pharmaceutical Association (APhA)
Assogenerici (Italy)
Blue Cross Blue Shield Association (BCBSA)
British Generic Manufacturers Association (BGMA)
Centers for Medicare and Medicaid Services (US)
China Food and Drug Administration (CFDA)
Congressional Budget Office (US)
Depart of Health (UK)
Department of Pharmaceuticals (India)
European Commission
European Generic Medicines Association (EGA)
European Medicines Agency (EMA)
Farmácia Popular (Popular Drugstores) (Brazil)
Federal Commission for the Protection against Sanitary Risk (COFEPRIS) (Mexico)
Federal Health Monitoring System (Germany)
Federal Joint Committee (Germany)
General Directorate of Pharmaceuticals and Pharmacy (GDPP) (Turkey)
Generic Pharmaceutical Association (GPhA) (US)
Generics and Biosimilars Initiative (GaBi)
German Association of Pharmacists (ABDA)
International Union of Pure and Applied Chemistry
Katholieke Universiteit Leuven (KU Leuven)
Leonard Davis Institute for Health Economics (University of Pennsylvania)
Mexican Institute of Social Security
Ministry of Health (Turkey)
Ministry of Health and Welfare (South Korea)
Ministry of Health, Labour and Welfare (MHLW) (Japan)
Ministry of Industry and Trade (Russia)
National Development and Reform Commission (NDRC) (China)
National Health Service (NHS) (UK)
National Pharmaceutical Pricing Authority (NPPA) (India)
Pan American Health Organization (PAHO)
Pharmaceutical and Medical Devices Agency (PMDA) (Japan)
Pharmaceutical Manufacturers Association of Turkey (IEIS) (Turkey)
Progenericos (Brazil)
Public Health Institution (Turkey)
Seguro Popular (Popular Insurance) (Mexico)
Servicio Sanitario Nazionale (SSN) (Italy)
Social Security Institution (SSI) (Turkey)
State Intellectual Property Office (China)
Statutory Health Insurance (SHI) (Germany)
Tufts Center for the Study of Drug Development
Turkish Association of Research-Based Pharmaceutical Companies (AIFD) (Turkey)
Unified Health System (SUS) (Brazil)
United Nations' Department of Economic and Social Affairs
United States Adopted Name (USAN) Council
University of Amsterdam
US Census Bureau
US Federal Trade Commission
US Food and Drug Administration (FDA)
US Patent and Trademark Office
Veteran Affairs Medical Center, Philadelphia
World Health Organization (WHO)
World Trade Organization (WTO)


【レポートのキーワード】

ジェネリック医薬品、後発医薬品

★調査レポート[ジェネリック医薬品のグローバル市場(2014-2024)] ( Generic Drugs: World Market 2014-2024
& Future Prospects for Leading Companies / Visiongain-4052624) 販売に関する免責事項
[ジェネリック医薬品のグローバル市場(2014-2024)] ( Generic Drugs: World Market 2014-2024
& Future Prospects for Leading Companies / Visiongain-4052624) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆